

GLAXOSMITHKLINE PLC  
Form 6-K  
March 13, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 6-K**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

**13 March 2013**

**GlaxoSmithKline plc**

**GlaxoSmithKline Capital plc**  
(Name of registrant)

**GlaxoSmithKline Capital Inc.**  
(Name of registrant)

**980 Great West Road,**

**1105 North Market Street,**

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

**Brentford,**

**Suite 622, Wilmington,**

**Middlesex, TW8 9GS**

**Delaware 19801**

**(Address of principal executive offices)**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

THIS REPORT ON FORM 6-K SHALL BE DEEMED TO BE INCORPORATED BY REFERENCE IN THE PROSPECTUS INCLUDED IN THE REGISTRATION STATEMENT ON FORM F-3 (FILE NO. 333-172621) OF GLAXOSMITHKLINE PLC, GLAXOSMITHKLINE CAPITAL INC. AND GLAXOSMITHKLINE CAPITAL PLC AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS FURNISHED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

---

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. hereby incorporate by reference the following exhibit to this report on Form 6-K into their Registration Statement on Form F-3 (File Nos. 333-172621, 333-172621-01, 333-172621-02).

| Exhibit<br>No. | Description of Document                                         |
|----------------|-----------------------------------------------------------------|
| 12.1           | Statement of Computation of Ratio of Earnings to Fixed Charges. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc  
GlaxoSmithKline Capital plc and  
GlaxoSmithKline Capital Inc.**

(Registrants)

Date: March 13, 2013

By:

/s/ VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc  
GlaxoSmithKline Capital plc and  
GlaxoSmithKline Capital Inc.